E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
|
E.1.1.1 | Medical condition in easily understood language |
Recurrent or metastatic cancer of the head and neck |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective:
• Phase Ib: to assess the feasibility and safety of the addition of cetuximab to methotrexate for recurrent or metastatic SCCHN
• Phase II: to assess the efficacy of the addition of cetuximab to methotrexate for recurrent or metastatic SCCHN
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives:
In both the phase Ib and phase II
• To assess overall survival (OS)
• To assess response rate (RR)
• To assess toxicity
• To assess quality of life (QoL)
• To assess HPV positivity in relation to PFS/OS/response |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Histology and disease stage
Recurrent or metastatic SCCHN.
No prior systemic treatment for recurrent or metastatic disease.
Primary site: oral cavity, oropharynx, hypopharynx or larynx.
Time between prior treatment and inclusion in the study (> 3 months).
General conditions
Written informed consent.
WHO performance status 0-2.
Normal number of neutrophils and trombocytes.
Normal hepatic function.
Renal function: calculated creatinin clearance > 60ml/min. |
|
E.4 | Principal exclusion criteria |
General conditions
Serious active infections.
Pregnancy or lactation.
Patients (M/F) with reproductive potential not implementing adequate contraceptives measures.
Prior history
Prior treatment with EGFR inhibitors or methotrexate.
Concomitant treatments
Concomitant (or within 4 weeks before randomization) administration of any other experimental drug under investigation.
Concurrent treatment with any other anti-cancer therapy.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoints:
• Phase Ib: Toxicity scored with CTC v 4.0*; dose limiting toxicity (DLT) during the first 4 weeks after start of the combination
• Phase II: PFS
*Toxicity scored according CTC v 4.0 will be done during the complete study period both in the phase Ib and phase II study |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Phase Ib: Toxicity scored with CTC v 4.0*; dose limiting toxicity (DLT) during the first 4 weeks after start of the combination
After end of the study treatment, the patient will be followed for PFS (in case PD was not the reason to stop treatment) and OS. In case the reason to stop was not PD, tumor measurements will be performed every 8 weeks and PS will be recorded. In case the patient will not attend the clinic anymore, we will contact the general practitioner for survival data. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints:
• OS
• RR according to RECIST 1.1
• Quality of life (QoL) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After end of the study treatment, the patient will be followed for PFS (in case PD was not the reason to stop treatment) and OS. In case the reason to stop was not PD, tumor measurements will be performed every 8 weeks and PS will be recorded. In case the patient will not attend the clinic anymore, we will contact the general practitioner for survival data.
Efficacy:
Every 8 weeks CT or MRI scanning will be done for tumor evaluation according to RECIST 1.1 (21).
The timing of QoL and local symptom assessments will be at baseline after 8 weeks, 24 weeks, after 1 year and at PD. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |